Every few years, certain companies quietly push the world forward not through hype or headlines, but through consistent science, engineering, and innovation.

As we move toward the end of 2025, many investors are asking the same question: Which industries could shape the future before 2026?

Some of these players aren’t household names. They don’t dominate the news cycle. But their financial results and strategic milestones are starting to paint a clearer picture a picture of progress, risk, and potential opportunity.

In this breakdown, we’ll explore two companies in two very different industries: advanced gene-editing biotechnology and next-generation nuclear energy. Both operate on the cutting edge. Both face challenges. And both could influence major global shifts in the years ahead.

This review is purely educational a way to help readers understand what's happening behind the headlines.

1. Intellia Therapeutics (NTLA): A Bold Player in Gene Editing Innovation

Intellia Therapeutics, based in Massachusetts, is one of the pioneers of CRISPR gene-editing technology. Their mission is ambitious:
develop real treatments that can edit human DNA to stop genetic diseases at their source.

It’s high-risk science with high potential impact and their latest Q3 2025 financial results offer a clearer look at how they’re progressing.

Cash Position: $193.39 Million (Up from $189.18M)

Intellia’s cash and cash equivalents rose slightly, adding about $4 million since December 2024.
While this may seem small, in biotech it’s meaningful. Cash is the engine that keeps research moving. A stable cash balance signals that the company is managing its liquidity well despite heavy R&D costs.

Revenue Growth: $13.78M vs. $9.11M (Q3 YoY)

Revenue increased by more than 50% year-over-year.
For a company still in clinical development, this usually reflects:

milestone payments

collaboration revenue

research partnerships

It’s encouraging but biotech revenue can swing sharply from quarter to quarter, so consistency is something investors monitor closely.

Operating Loss Improves: $111.48M vs. $144.77M

Intellia reduced its operating loss by over $33 million.
This signals better spending discipline and more efficient allocation of R&D resources.

Operating Expenses Drop: $125.26M vs. $153.88M

A nearly $29 million reduction in operating expenses shows the company is controlling costs while still advancing its pipeline.

Net Loss Per Share Improves: $0.92 vs. $1.34

A 31% improvement year-over-year.
This reflects a mix of stronger revenue and tighter expense management.

Key Scientific & Corporate Updates for Intellia

Intellia’s scientific news this year is just as significant as its financial progress:

• Positive Phase 1/2 Data for Lonvoguran Ziclumeran (lonvo-z)

Encouraging results for hereditary angioedema — a rare but serious disease.

• Completion of Enrollment for the Global Phase 3 HAELO Study

A major milestone that brings them closer to potentially launching a commercial treatment.

• First Patient Dosed in MAGNITUDE-2 Phase 3 Study for Nexiguran Ziclumeran (nex-z)

A one-time gene editing–based treatment for ATTR amyloidosis, another high-impact therapeutic area.

• Inducement Grants under Nasdaq Rule 5635(c)(4)

This suggests continued team expansion and strategic hiring.

Risks for Intellia

Biotech remains one of the most volatile industries because:

Clinical trials may fail.

Regulatory approval is slow and expensive.

Competition in gene therapy is intense.

Still, Intellia is showing financial discipline, scientific progress, and operational efficiency — all important signals in early-stage biotech.

2. NuScale Power (SMR): Redefining Clean Energy Through Small Modular Reactors

Switching from biotechnology to clean energy, NuScale Power is a U.S.-based leader in small modular reactors (SMRs), compact nuclear systems designed to deliver clean, stable power with improved safety features.

Nuclear energy is controversial for some, essential for others but SMRs are gaining global momentum, and NuScale’s recent results show why.

Cash Position: $407.58M vs. $401.55M

A small increase, but it shows that NuScale maintains strong liquidity as it develops multi-billion-dollar projects.

Revenue Surge: $8.24M vs. $475K

This is one of the standout numbers:
Revenue jumped by more than 1,600%.

This likely reflects engineering contracts, project agreements, or government-supported initiatives, a big shift from early-stage development toward commercial implementation.

R&D Spending: $11.05M

Consistent with a company pushing hard into innovation, testing, and regulatory compliance.

Net Loss Per Share: $1.85 vs. $0.18

Even with rising revenue, losses widened.
This is common in capital-heavy industries like nuclear energy where scale-up costs hit before profitability does.

Total Assets: $883.13M vs. $544.67M

A major increase of over $338 million, indicating growth in long-term investments and infrastructure.

Short-Term Investments: $346.99M vs. $45M

This suggests a strategic allocation of excess cash into short-term securities.

Strategic Highlights for NuScale

NuScale’s momentum extends beyond numbers:

Supporting ENTRA1 Energy’s $25 billion U.S. power infrastructure program

Achieving Standard Design Approval from the U.S. Nuclear Regulatory Commission

Launching an Energy Exploration Center with South Carolina State University

Supporting a 6-gigawatt SMR deployment program with TVA and ENTRA1 Energy

These moves position NuScale as a key player in the future of clean, scalable nuclear power.

Risks for NuScale

Nuclear development faces:

complex regulatory timelines

significant capital requirements

public perception challenges

long project cycles before revenue materializes

Still, the company’s technology and partnerships give it a strong strategic runway.

Which Company Stands Out?

Intellia is reshaping what’s possible in human medicine.
NuScale is reshaping how the world approaches clean energy.

Both are bold.
Both carry risks.
Both operate in transformative industries that could look very different by 2026.

Conclusion & Call to Action

If you enjoy deep dives into emerging industries, financial breakdowns, and trend analysis, feel free to explore more insights on this blog.

👉 Share this article with someone who loves learning about innovative companies.
👉 Subscribe to stay updated on future stock breakdowns.
👉 Leave a comment with which industry you think will grow faster in the next decade, biotech or clean energy?

Disclaimer

This article is for educational and informational purposes only. It is not financial advice, and it does not recommend buying, selling, or holding any security. All investing involves risk. Always conduct personal research or consult a licensed financial professional before making investment decisions.